Skip to main content


Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells

Fig. 3

CD133-positive HCC cells have an efficient ROS defense system. a Western blot analysis of CD133 after sorting of CD133-negative and CD133-positive HCC from Huh7 cells. b Expression of CSC-related cell surface markers (EpCAM, CD90, CD44, CD24, AFP) were examined in CD133-negative HCC and CD133-positive HCC by western blotting. c ROS accumulation in CD133-negative and CD133-positive HCC was measured after treatment with 200 μM H2O2 for 20 min. The data shown were from three independent experiments relative to the value for control. d CD133-negative and CD133-positive HCC were treated with the indicated concentrations of MTX, cisplatin, and As2O3. To examine the effect of radiation, cells were treated with 10 Gy radiation. For ROS level measurement, cells were stained with CM-H2DCFDA and analyzed by the HCS system after 12 h treatment with anti-cancer drugs and radiation treatment

Back to article page